DWC202405 + DWC202313 + DWC202314

DWC202405 + DWC202313 + DWC202314 is an investigational fixed-dose triple combination therapy under phase III clinical evaluation for the treatment of essential hypertension. This combination is being studied specifically in patients whose hypertension is inadequately controlled with DWC202405 and DWC202313, aiming to improve blood pressure management by adding a third antihypertensive agent (DWC202314) to the regimen. The precise molecular identities, classes, and mechanisms of the three components have not been publicly disclosed in sponsor or trial registry summaries available to date. The product is being developed by Daewoong Pharmaceutical and targets improved efficacy and safety through a multi-mechanistic approach typical for combination antihypertensive therapy, potentially combining agents from complementary pharmacological classes (common classes include angiotensin receptor blockers, calcium channel blockers, and diuretics) to maximize antihypertensive effect and minimize adverse events.[1][3][5][8]